Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $372.3 million.

  • Coherus Oncology's Total Current Liabilities rose 2596.07% to $372.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.3 million, marking a year-over-year increase of 2596.07%. This contributed to the annual value of $283.0 million for FY2024, which is 1470.59% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Total Current Liabilities is $372.3 million, which was up 2596.07% from $263.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Total Current Liabilities high stood at $538.3 million for Q1 2024, and its period low was $123.4 million during Q1 2023.
  • Moreover, its 5-year median value for Total Current Liabilities was $257.6 million (2021), whereas its average is $261.6 million.
  • Per our database at Business Quant, Coherus Oncology's Total Current Liabilities soared by 33620.14% in 2024 and then crashed by 5262.11% in 2025.
  • Coherus Oncology's Total Current Liabilities (Quarter) stood at $165.3 million in 2021, then decreased by 16.11% to $138.7 million in 2022, then surged by 139.21% to $331.8 million in 2023, then dropped by 14.71% to $283.0 million in 2024, then skyrocketed by 31.56% to $372.3 million in 2025.
  • Its last three reported values are $372.3 million in Q3 2025, $263.6 million for Q2 2025, and $255.0 million during Q1 2025.